Healthpeak Properties stock reaction and recent performance

Healthpeak Properties (DOC) has drawn investor attention after recent trading left the stock at a last close of US$19.07, with returns down 2.0% over the past day and 4.0% over the past week.

Despite this short term pullback, the stock shows a gain of 17.1% over the past month and 9.5% over the past 3 months, while the 1 year total return stands at 19.5%.

For investors, the picture is that short term momentum has cooled after a strong recent run, with the 30 day share price return of 17.1% feeding into a 1 year total shareholder return of 19.5%.

If you are comparing Healthpeak with other opportunities in real estate and beyond, this could be a good moment to broaden your search and check out 20 top founder-led companies

With Healthpeak trading at US$19.07 and showing an indicated 42.7% intrinsic discount alongside a value score of 2, the key question is whether this gap signals mispricing or whether the market is already factoring in expectations for future growth.

Most Popular Narrative: 8.5% Undervalued

Healthpeak Properties' most followed narrative pegs fair value at $20.83, a touch above the last close at $19.07, putting the spotlight firmly on whether the market is underpricing the story in that gap.

The analysts have a consensus price target of $20.83 for Healthpeak Properties based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $29.0, and the most bearish reporting a price target of just $17.0.

Curious what kind of revenue path, margin profile, and future earnings multiple are being baked into that fair value, and why the discount rate matters so much here? The narrative highlights a specific growth glide path, a thinner profitability outlook, and a much higher earnings multiple than the sector usually commands. These elements are combined into one valuation case that is very different from the current share price.

Using an 8.28% discount rate, this narrative effectively asks you to weigh a modest upside to $20.83 against a wide spread of possible outcomes for revenue, earnings, and valuation multiples over the coming years.

Result: Fair Value of $20.83 (UNDERVALUED)

However, this narrative can quickly look different if tenant credit issues in the lab portfolio deepen, or if tighter capital markets push borrowing costs and refinancing risk higher.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another way to look at valuation

The analyst narrative leans on earnings forecasts and an implied P/E of 111.1x in 2029, but the current market already prices Healthpeak at about 59.3x earnings versus 20.8x for the Global Health Care REITs group and a fair ratio of 29.3x. That gap suggests sizeable valuation risk if sentiment cools.

For a closer look at how those earnings multiples stack up against peers, and what the fair ratio implies if the market moves closer to it, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and concern running through this story, it makes sense to look at the underlying data yourself and decide quickly where you stand. You can start with the 1 key reward and 4 important warning signs

Looking for more investment ideas?

If Healthpeak does not quite fit your plan, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Scan for potential value opportunities by checking stocks highlighted in the 47 high quality undervalued stocks.
• Prioritize financial resilience and stability by reviewing companies in the solid balance sheet and fundamentals stocks screener (47 results).
• Target consistent income streams by assessing stocks featured in the 10 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.